Alnylam Pharmaceuticals, Inc. (ALNY) Cash Flow Statement

The gap between net income and operating cash flow is stark, particularly in 2026Q2 where OCF/NI stood at 0.46, suggesting that reported profitability is not yet translating into cash at the same pace. The large working capital changes, especially the -$281.7M in 2026Q1, indicate that revenue growth is consuming cash through receivables and inventory, which may normalize as the commercial infrastructure matures. Investors should monitor whether cash conversion improves as the company scales, or if the persistent SBC expense continues to inflate earnings relative to cash generation.

The trajectory shows a clear inflection from negative FCF in early 2024 to positive and growing through 2025, driven by the Amvuttra launch and milestone payments. However, the 2026Q2 FCF margin of 3.1% is a sharp drop from the 25.1% in 2025Q3, indicating that the recent quarter's cash generation is not yet sustainable. The volatility suggests that FCF is heavily influenced by one-time collaboration payments and working capital swings, so the underlying run-rate may be more modest than the peak quarters imply.

CapEx intensity is low, with the highest quarter at 2.7% of revenue in 2026Q2, which is typical for a biotech that outsources manufacturing. This suggests that the company's cash flow is not constrained by maintenance capex, but rather by the high R&D and SG&A costs that are expensed as incurred. The low capital intensity supports the view that Alnylam's platform is scalable, but it also means that future growth will depend on continued investment in clinical trials and commercial expansion, which are captured in operating expenses rather than capex.

The large negative working capital changes in several quarters, particularly 2026Q1 and 2025Q3, indicate that revenue growth is consuming cash through receivables and inventory, likely due to the expansion of Amvuttra and new geographic launches. These swings are not necessarily a sign of operational inefficiency but rather the lumpy nature of collaboration payments and the need to build inventory ahead of demand. Investors should expect continued volatility in working capital as the company scales, but the underlying trend in collections and payables appears manageable given the high gross margins.

The absence of capital returns is consistent with a growth-stage biotech that is reinvesting all cash into its pipeline and commercial infrastructure. The company has instead relied on non-dilutive partnerships, such as the Roche deal for Zilebesiran, to fund development, which reduces the need for equity issuance. However, the high debt-to-equity ratio of 1.62 suggests that the balance sheet is leveraged, and investors should monitor whether the company will need to raise additional capital or refinance debt if cash flows decelerate.

The cumulative divergence is positive, with operating cash flow exceeding net income by a wide margin, largely due to non-cash charges like depreciation and stock-based compensation. This suggests that the company's earnings quality is actually higher than the recent quarterly conversion ratios imply, as the large working capital swings are timing-related. However, the reliance on milestone payments and the volatility in quarterly cash flow warrant caution, as the cumulative figure may be flattered by one-time collaboration receipts that are not recurring.